Quanterix Targets H2 2026 Cash-Flow Breakeven with $85M Synergies and $100M Cash
Quanterix reported a Q4 2025 adjusted EBITDA loss of $7.9 million, improving from the prior quarter, and targets $85 million in cost synergies by end-Q1 2026 to achieve cash flow breakeven in H2 2026. The company holds over $100 million in cash with zero debt and plans a steady cadence of assay launches throughout 2026.
1. Q4 2025 Financial Performance
Quanterix reported an adjusted EBITDA loss of $7.9 million in Q4 2025, narrowing from the prior quarter, supported by operational efficiencies. The balance sheet includes over $100 million in cash and zero debt, underscoring liquidity as R&D and commercialization continue.
2. Cost Synergy and Breakeven Roadmap
The company aims to deliver $85 million in cost synergies by end-Q1 2026 through manufacturing optimization, headcount rationalization, and supply-chain enhancements. These savings are critical to achieving cash-flow breakeven in the second half of 2026 under the current financial plan.
3. Product Pipeline and Strategic Initiatives
Quanterix expects a steady cadence of assay launches throughout 2026, leveraging its Simoa ONE platform’s early access program to drive commercial uptake. Management targets FDA 510(k) approval for its Alzheimer’s diagnostic by Q4 2026 while expanding service partnerships in spatial biology and proteomics post-Akoya acquisition.